Source: IVD News

On May 19, 2025, 23andMe officially announced that Regeneron will$256 million (approximately 1.85 billion yuan)Consideration for the acquisition of consumer genetic testing company 23andMe.

Under the terms of the agreement, Regeneron will acquire nearly all of the company's assets, including Personal Genome Service (PGS) and the Complete Health and Research Services business line, for $256 million. The agreement does not include the acquisition of the company’s Lemonaid Health subsidiary, and the company plans to orderly wind down the operations of this subsidiary in accordance with the agreement.

On March 23, 2025, 23andMe announced that the company had filed for bankruptcy protection and was seeking a buyer. On April 18, 23andMe disclosed the requirements for the sale.

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops, and commercializes transformative medicines for serious diseases. Founded and led by physician-scientists, the company's unique ability to continuously translate science into medicine has driven numerous approved therapies and investigational candidates, most of which originate from its own laboratories. Regeneron’s portfolio of medicines and pipeline aim to help patients with eye diseases, allergic and inflammatory conditions, cancer, cardiovascular and metabolic diseases, neurological disorders, blood-related conditions, infectious diseases, and rare diseases.

As a pioneer in the field of genetic testing, 23andMe was founded in 2006 by Anne Wojcicki, the ex-wife of Google co-founder Sergey Brin.The name "23andMe" comes from the 23 pairs of chromosomes in the human genome and the close relationship between individuals and their genes. It is the first company to receive FDA approval to directly provide genealogical chromosome testing to the general public.

Since its establishment, the company has attracted significant capital attention, with investors including renowned institutions such as WuXi AppTec, Fidelity Investments, Sequoia Capital USA, and GlaxoSmithKline. According to statistics from CBINSIGHT,23andMe has completed a total of 26 rounds of financing.

In 2013, the U.S. FDA issued a warning letter to 23andMe, questioning the health claims of its DNA tests. However, in 2017, the company received de novo authorization from the FDA for 10 genetic health risk tests. 23andMe went public in 2021, with its market value reaching a peak of $6 billion.Subsequently, the stock price plummeted, revenue fell short of covering losses, and the company gradually went downhill.